Inventor · disambiguated record
Matthew J. Lamarche
Also filed as: LAMARCHE MATTHEW J · LAMARCHE MATTHEW JAMES
26 granted patents·9 pending applications·120 citations·filing 1999–2024
95Inventor score
Files withNOVARTIS AG19UNIV PENNSYLVANIA5CHEN CHRISTINE HIU-TUNG3MILLENNIUM PHARM INC3CHEN ZHUOLIANG2
Top patents by PatentIndex Score
35 records- 0192US10968235B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2019·Granted Apr 6, 2021·3 cites·3 claims
- 0292US10934285B2Compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2017·Granted Mar 2, 2021·5 cites·5 claims
- 0392US10077276B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2CHEN CHRISTINE HIU TUNG·Filed 2015·Granted Sep 18, 2018·15 cites·22 claims
- 0490US10336774B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2018·Granted Jul 2, 2019·7 cites·22 claims
- 0590US10093646B21-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2CHEN CHRISTINE HIU TUNG·Filed 2015·Granted Oct 9, 2018·7 cites·10 claims
- 0690US9815813B21-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2CHEN ZHUOLIANG·Filed 2015·Granted Nov 14, 2017·13 cites·8 claims
- 0788US10301278B21-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2NOVARTIS AG·Filed 2017·Granted May 28, 2019·8 cites·7 claims
- 0886US10287266B2Compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2016·Granted May 14, 2019·8 cites·13 claims
- 0984US7368585B2Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereofUNIV PENNSYLVANIA·Filed 2006·Granted May 6, 2008·4 cites·2 claims
- 1081US10975080B2Compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2016·Granted Apr 13, 2021·2 cites·3 claims
- 1181US7723536B2Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereofUNIV PENNSYLVANIA·Filed 2008·Granted May 25, 2010·2 cites·2 claims
- 1279US2024199609A1Compounds and compositions for inhibiting the activity of shp2NOVARTIS AG·Filed 2023·Application pending·0 cites
- 1378US10130629B2Pharmaceutical combinationsNOVARTIS AG·Filed 2016·Granted Nov 20, 2018·3 cites·7 claims
- 1478US8110687B2Bicyclic compounds with kinase inhibitory activityCALDERWOOD EMILY F·Filed 2006·Granted Feb 7, 2012·7 cites·19 claims
- 1577US2022073537A1N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2NOVARTIS AG·Filed 2021·Application pending·0 cites
- 1676US6870058B2Compounds which mimic the chemical and biological properties of discodermolideUNIV PENNSYLVANIA·Filed 2000·Granted Mar 22, 2005·8 cites·22 claims
- 1775US11952386B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2021·Granted Apr 9, 2024·0 cites·12 claims
- 1875US6242616B1Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivativesUNIV PENNSYLVANIA·Filed 1999·Granted Jun 5, 2001·19 cites·14 claims
- 1975US2022348553A11-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of shp2NOVARTIS AG·Filed 2022·Application pending·0 cites
- 2074US12209098B2N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2021·Granted Jan 28, 2025·0 cites·26 claims
- 2171US6921821B2Antagonists of melanin concentrating hormone receptorABBOTT LAB·Filed 2003·Granted Jul 26, 2005·7 cites·23 claims
- 2270US11905283B2Compounds and compositions for inhibiting the activity of SHP2NOVARTIS AG·Filed 2020·Granted Feb 20, 2024·0 cites·8 claims
- 2369US11401259B21-Pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2NOVARTIS AG·Filed 2020·Granted Aug 2, 2022·0 cites·4 claims
- 2469US7652041B2Cinnamide and hydrocinnamide derivatives with kinase inhibitory activityMILLENNIUM PHARM INC·Filed 2006·Granted Jan 26, 2010·1 cites·39 claims
- 2566US10308660B2Compounds and compositions for inhibiting the activity of SHP2CHEN ZHUOLIANG·Filed 2016·Granted Jun 4, 2019·1 cites·20 claims
- 2666US2021309663A1Compounds and compositions for inhbiting the activity of shp2NOVARTIS AG·Filed 2021·Application pending·0 cites
- 2765US2022089597A1Compounds and compositions for inhbiting the activity of shp2NOVARTIS AG·Filed 2021·Application pending·0 cites
- 2864US10774065B21-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2CHEN CHRISTINE HIU TUNG·Filed 2018·Granted Sep 15, 2020·0 cites·3 claims
- 2963US2025092036A1Compounds and compositions for modulating the activity of erkNOVARTIS AG·Filed 2024·Application pending·0 cites
- 3062US12053470B2Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitorNOVARTIS AG·Filed 2022·Granted Aug 6, 2024·0 cites·7 claims
- 3153US2005245563A1Chk-1 inhibitorsMILLENNIUM PHARM INC·Filed 2004·Application pending·0 cites
- 3243US2006035920A1Chk-1 inhibitorsMILLENNIUM PHARM INC·Filed 2005·Application pending·0 cites
- 3342US2019343836A1Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitorNOVARTIS AG·Filed 2018·Application pending·0 cites
- 3440US7652031B2Compounds which mimic the chemical and biological properties of discodermolideUNIV PENNSYLVANIA·Filed 2002·Granted Jan 26, 2010·0 cites·3 claims
- 3535US8183341B2Antibacterial compounds and processes for its productionLAMARCHE MATTHEW J·Filed 2007·Granted May 22, 2012·0 cites·14 claims
Join the waitlist — get patent alerts
Get an alert when Matthew J. Lamarche files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →